APOA1 and amyotrophic lateral sclerosis: Using the same dose of ApoA1 in the treatment of symptomatic ALS mice, results demonstrated substantially reduced EB leakage into the parenchyma of cervical and lumbar spinal cords in ALS mice of both genders.